CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

3 days ago · HOUSTON, TX / ACCESSWIRE / November 15, 2024 / CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) ("CNS" or the "Company"), a biopharmaceutical company specializing in the …

CouponFollow Extension

$5
OFF

CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results

1 week from now

3 days ago · Summary of Financial Results for the Third Quarter 2024 The net loss for the three months ended September 30, 2024 was approximately $5.6 million compared to …

morningstar.com

$14
OFF

Tonix Pharmaceuticals Reports Third Quarter 2024 Financial …

1 week from now

6 days ago · Net loss available to common stockholders was approximately $14.2 million, or $0.23 per share, basic and diluted, for the third quarter 2024, compared to net loss available to …

businessinsider.com

$2
OFF

CNS Pharmaceuticals Reports Second Quarter 2024 Financial Results

1 week from now

Aug 15, 2024 · Summary of Financial Results for the Second Quarter 2024. The net loss for the three months ended June 30, 2024 was approximately $2.5 million compared to approximately …

morningstar.com

$4
OFF

Plus Therapeutics Reports Third Quarter 2024 Financial Results

1 week from now

3 days ago · third quarter 2024 financial results The Company’s cash and investments balance was $4.8 million at September 30, 2024 compared to $8.6 million at December 31, 2023 .

nasdaq.com

$64
OFF

Lexicon Pharmaceuticals Reports Third Quarter 2024 Financial …

1 week from now

6 days ago · Net Loss: Net loss for the third quarter of 2024 was $64.8 million, or $0.18 per share, as compared to a net loss of $50.5 million, or $0.21 per share, in the corresponding period in …

morningstar.com

$8
OFF

Marinus Pharmaceuticals Provides Business Update And Reports …

1 week from now

6 days ago · Marinus Pharmaceuticals Provides Business Update and Reports Third Quarter 2024 Financial Results ZTALMY ® (ganaxolone) Q3 2024 net product revenue of $8.5 million …

businesswire.com

FAQs about CNS Pharmaceuticals Reports Third Quarter 2024 Financial Results Coupon?

Will CNS pharmaceuticals report topline results in 2025?

CNS Pharmaceuticals expects to report topline results from its potentially pivotal study of Berubicin in the first half of 2025. The FDA has granted CNS Pharmaceuticals Fast Track Designation for Berubicin which enables more frequent interactions with the agency for guidance on expediting the development and review process. ...

What did Marinus Pharmaceuticals do in the third quarter 2024?

RADNOR, Pa., November 12, 2024 -- (BUSINESS WIRE)-- Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and financial results for the third quarter ended September 30, 2024. ...

Does CNS pharmaceuticals have a recurrent GBM?

CNS Pharmaceuticals plans to engage the FDA and obtain feedback on the design of a study focused on the registration of TPI 287 in recurrent GBM. Summary of Financial Results for the Third Quarter 2024 ...

What was the net loss available to common stockholders in Q3 2024?

Net loss available to common stockholders was approximately $14.2 million, or $0.23 per share, basic and diluted, for the third quarter 2024, compared to net loss available to common stockholders of $28.0 million, or $38.63 per share, basic and diluted, for the same period in 2023. ...

What does CNS pharmaceuticals do?

CNS Pharmaceuticals a clinical-stage pharmaceutical company developing a pipeline of anti-cancer drug candidates for the treatment of primary and metastatic cancers of the brain and central nervous system malignancies. ...

When will CNS pharmaceuticals report a pivotal study of berubicin?

CNS Pharmaceuticals expects to report primary analysis data from its potentially pivotal study of Berubicin in the first half of 2025. The FDA has granted CNS Pharmaceuticals Fast Track Designation for Berubicin which enables more frequent interactions with the agency for guidance on expediting the development and review process. ...